Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study

Background: The role of beta-blockers in acute myocardial infarction patients without heart failure and with preserved left ventricular ejection fraction (LVEF ≥ 50%) is unknown. Our study aimed to retrospectively analyze the associations of beta-blockers on such patients. Methods: This is a multice...

Full description

Bibliographic Details
Main Authors: Duan, Q. (Author), Liu, J. (Author), Luo, R. (Author), Qin, S. (Author), Wen, X.-S (Author), Xiao, J. (Author), Zhang, D.-Y (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 03371nam a2200253Ia 4500
001 10.1186-s12872-022-02631-8
008 220510s2022 CNT 000 0 und d
020 |a 14712261 (ISSN) 
245 1 0 |a Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study 
260 0 |b BioMed Central Ltd  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s12872-022-02631-8 
520 3 |a Background: The role of beta-blockers in acute myocardial infarction patients without heart failure and with preserved left ventricular ejection fraction (LVEF ≥ 50%) is unknown. Our study aimed to retrospectively analyze the associations of beta-blockers on such patients. Methods: This is a multicenter, retrospective study. After screening 5,332 acute myocardial infarction patients, a total of 2519 patients without heart failure and with LVEF ≥ 50% were included. The patients were divided into two groups: the prescribed (n = 2049) and unprescribed (n = 470) beta-blockers group. The propensity score inverse probability treatment weighting was used to control confounding factors. We analyzed the associations between beta-blockers and outcomes in the short-term (1-year) and long-term (median, 3.61 years). Results: The primary outcome was all-cause mortality. The secondary outcomes were all-cause rehospitalization, cardiac death, recurrent myocardial infarction, new-onset heart failure rehospitalization. This study shows no statistically significant association between discharged with beta-blockers and all-cause mortality, either in the short-term [IPTW Adjusted, HR 1.02; 95%CI 0.43–2.40; P = 0.966] or long-term [IPTW Adjusted, HR 1.17; 95%CI 0.70–1.94; P = 0.547]. Discharged with beta-blockers was significantly associated with a reduced risk of short-term recurrent myocardial infarction [IPTW Adjusted, HR 0.44; 95%CI 0.20–0.97; P = 0.043], but there was no long-term relationship [IPTW Adjusted, HR 1.11; 95%CI 0.61–2.03; P = 0.735]. Other outcomes, such as new-onset heart failure rehospitalization and all-cause rehospitalization, were not observed with meaningful differences in either the short- or long-term. The results of sensitivity analysis were consistent with this. Conclusions: Beta-blockers might be associated with a reduced risk of recurrent myocardial infarction in patients without heart failure and with preserved left ventricular ejection fraction after acute myocardial infarction, in the short term. Beta-blockers might not be related to all-cause mortality in those patients, either in the short-term or long-term. Clinical trial registration Influence of Beta-blockers on Prognosis in Patients with Acute Myocardial Infarction Complicated with Normal Ejection Fraction, NCT04485988, Registered on 24/07/2020. Retrospectively registered. © 2022, The Author(s). 
650 0 4 |a Acute myocardial infarction 
650 0 4 |a Beta-blockers 
650 0 4 |a Heart failure 
650 0 4 |a Left ventricular ejection fraction 
700 1 |a Duan, Q.  |e author 
700 1 |a Liu, J.  |e author 
700 1 |a Luo, R.  |e author 
700 1 |a Qin, S.  |e author 
700 1 |a Wen, X.-S.  |e author 
700 1 |a Xiao, J.  |e author 
700 1 |a Zhang, D.-Y.  |e author 
773 |t BMC Cardiovascular Disorders